This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Go back to News
Former Voyager CEO Andre Turenne makes a comeback with Atlas-backed covalent drug biotech
In February, Endpoints News reported that Turenne had signed on to head a stealth mode Atlas Venture-backed biotech EoCys. After a name change in March, EoCys has evolved into Matchpoint Therapeutics, which is coming out of stealth with a $70 million Series A and a focus on making covalent drugs, or drugs that bind irreversibly.
